Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Translational platelet research in patients with coronary artery disease: what are the major knowledge gaps?

Gurbel PA, Roe MT, Jakubowski JA, Shah S, Erlinge D, Goodman SG, Huber K, Chan MY, Cornel JH, Tantry US, Ohman EM.

Thromb Haemost. 2012 Jul;108(1):12-20. doi: 10.1160/TH12-01-0039. Epub 2012 May 25. Review.

PMID:
22627684
2.

The cytochrome 2C19*2 and *3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention.

Hwang SJ, Jeong YH, Kim IS, Koh JS, Kang MK, Park Y, Kwak CH, Hwang JY.

Thromb Res. 2011 Jan;127(1):23-8. doi: 10.1016/j.thromres.2010.10.021.

PMID:
21075428
3.

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.

Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US, Gibson Q, Pollin TI, Post W, Parsa A, Mitchell BD, Faraday N, Herzog W, Gurbel PA.

JAMA. 2009 Aug 26;302(8):849-57. doi: 10.1001/jama.2009.1232.

4.

Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.

Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, Morath T, Schömig A, von Beckerath N, Kastrati A.

Circulation. 2010 Feb 2;121(4):512-8. doi: 10.1161/CIRCULATIONAHA.109.885194. Epub 2010 Jan 18.

5.

Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study.

Siller-Matula JM, Delle-Karth G, Lang IM, Neunteufl T, Kozinski M, Kubica J, Maurer G, Linkowska K, Grzybowski T, Huber K, Jilma B.

J Thromb Haemost. 2012 Apr;10(4):529-42. doi: 10.1111/j.1538-7836.2012.04639.x.

6.

Antiplatelet drug resistance and variability in response: the role of antiplatelet therapy monitoring.

Tantry US, Gurbel PA.

Curr Pharm Des. 2013;19(21):3795-815. Review.

PMID:
23286432
7.

Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients.

Zhang L, Chen Y, Jin Y, Qu F, Li J, Ma C, Yang J, Xu B, Wang H, Li X, Li Y, Zhang Y, Lu C, Yin T.

Thromb Res. 2013 Jul;132(1):81-7. doi: 10.1016/j.thromres.2013.05.006. Epub 2013 May 29.

PMID:
23726091
8.

The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients.

Gurbel PA, Bliden KP, Antonino MJ, Stephens G, Gretler DD, Jurek MM, Pakyz RE, Shuldiner AR, Conley PB, Tantry US.

J Thromb Haemost. 2010 Jan;8(1):43-53. doi: 10.1111/j.1538-7836.2009.03648.x. Epub 2009 Oct 11.

9.

Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting.

Bouman HJ, Harmsze AM, van Werkum JW, Breet NJ, Bergmeijer TO, Ten Cate H, Hackeng CM, Deneer VH, Ten Berg JM.

Heart. 2011 Aug;97(15):1239-44. doi: 10.1136/hrt.2010.220509. Epub 2011 May 31.

PMID:
21628721
10.

Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays.

Tsantes AE, Ikonomidis I, Papadakis I, Bonovas S, Gialeraki A, Kottaridi C, Kyriakou E, Kokori S, Douramani P, Kopterides P, Karakitsos P, Lekakis J, Kapsimali V.

Thromb Res. 2013 Aug;132(2):e105-11. doi: 10.1016/j.thromres.2013.06.015. Epub 2013 Jul 2.

PMID:
23830212
11.

The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial.

Gladding P, Webster M, Zeng I, Farrell H, Stewart J, Ruygrok P, Ormiston J, El-Jack S, Armstrong G, Kay P, Scott D, Gunes A, Dahl ML.

JACC Cardiovasc Interv. 2008 Dec;1(6):620-7. doi: 10.1016/j.jcin.2008.09.008.

12.

The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy.

Gurbel PA, Shuldiner AR, Bliden KP, Ryan K, Pakyz RE, Tantry US.

Am Heart J. 2011 Mar;161(3):598-604. doi: 10.1016/j.ahj.2010.12.011.

13.

Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention.

Ono T, Kaikita K, Hokimoto S, Iwashita S, Yamamoto K, Miyazaki Y, Horio E, Sato K, Tsujita K, Abe T, Deguchi M, Tayama S, Sumida H, Sugiyama S, Yamabe H, Nakamura S, Nakagawa K, Ogawa H.

Thromb Res. 2011 Dec;128(6):e130-6. doi: 10.1016/j.thromres.2011.07.028. Epub 2011 Aug 20.

PMID:
21862109
15.

Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention.

Bonello-Palot N, Armero S, Paganelli F, Mancini J, De Labriolle A, Bonello C, Lévy N, Maillard L, Barragan P, Dignat-George F, Camoin-Jau L, Bonello L.

Am J Cardiol. 2009 Dec 1;104(11):1511-5. doi: 10.1016/j.amjcard.2009.07.015.

PMID:
19932784
16.

High on-treatment platelet reactivity by ADP and increased risk of MACE in good clopidogrel metabolizers.

Marcucci R, Giusti B, Paniccia R, Gori AM, Saracini C, Valente S, Giglioli C, Parodi G, Antoniucci D, Gensini GF, Abbate R.

Platelets. 2012;23(8):586-93. doi: 10.3109/09537104.2012.658106. Epub 2012 Mar 5.

PMID:
22390861
17.

Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study.

Price MJ, Murray SS, Angiolillo DJ, Lillie E, Smith EN, Tisch RL, Schork NJ, Teirstein PS, Topol EJ; GIFT Investigators.

J Am Coll Cardiol. 2012 May 29;59(22):1928-37. doi: 10.1016/j.jacc.2011.11.068.

18.

Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention.

Hwang SJ, Jeong YH, Kim IS, Park KS, Kang MK, Koh JS, Park JR, Park Y, Koh EH, Kwak CH, Hwang JY, Kim S.

Circ Cardiovasc Interv. 2010 Oct;3(5):450-9. doi: 10.1161/CIRCINTERVENTIONS.110.949859. Epub 2010 Sep 7.

19.

Impact of gene polymorphisms, platelet reactivity, and the SYNTAX score on 1-year clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: the GEPRESS study.

Palmerini T, Calabrò P, Piscione F, De Servi S, Cattaneo M, Maffeo D, Toso A, Bartorelli A, Palmieri C, De Carlo M, Capodanno D, Barozzi C, Tomasi L, Della Riva D, Mariani A, Taglieri N, Reggiani LB, Bianchi R, De Rosa R, Mariani M, Podda G, Généreux P, Stone GW, Angiolillo DJ.

JACC Cardiovasc Interv. 2014 Oct;7(10):1117-27. doi: 10.1016/j.jcin.2014.04.020. Epub 2014 Sep 17.

20.

Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel.

Jang JS, Cho KI, Jin HY, Seo JS, Yang TH, Kim DK, Kim DS, Seol SH, Kim DI, Kim BH, Park YH, Je HG, Jeong YH, Lee SW.

Am J Cardiol. 2012 Aug 15;110(4):502-8. doi: 10.1016/j.amjcard.2012.04.020. Epub 2012 May 15.

PMID:
22591668

Supplemental Content

Support Center